Further Expansions and Positive Study Results Drive Healthcare Companies - Research Report on Agilent, Thermo Fisher, BG

  Further Expansions and Positive Study Results Drive Healthcare Companies -
Research Report on Agilent, Thermo Fisher, BG Medicine, Quest Diagnostics, and
                           Ironwood Pharmaceuticals

PR Newswire

NEW YORK, May 31, 2013

NEW YORK, May 31, 2013 /PRNewswire/ --

Editor Note: For more information about this release, please scroll to bottom.

Today, Wall Street Reports announced new research reports highlighting Agilent
Technologies Inc. (NYSE: A), Thermo Fisher Scientific Inc. (NYSE: TMO), BG
Medicine, Inc. (NASDAQ: BGMD), Quest Diagnostics Inc. (NYSE: DGX), and
Ironwood Pharmaceuticals, Inc. (NASDAQ: IRWD). Today's readers may access
these reports free of charge - including full price targets, industry analysis
and analyst ratings - via the links below.

Agilent Technologies Inc. Research Report

On May 28, 2013, Agilent Technologies Inc. (Agilent) expanded its presence in
Vietnam by announcing the opening of two new offices. Located in Hanoi and Ho
Chi Minh City, these offices will be fully equipped and staffed to provide
customers in Vietnam with sales, applications and support services. In Hanoi,
Agilent's Advantage Services Facility, a repair and calibration center for
electronic test instruments, will serve customers spanning industries such as
government, defense, education, and manufacturing. Agilent's Technology Demo
Center in Ho Chi Minh City will be equipped with cutting-edge bio-analytical
instruments used by scientists and researchers, enabling the Company to
collaborate with customers in Vietnam to develop applications and
methodologies for research and commercial implementations in the life sciences
and chemical analysis industries. Dr. Nick Roelofs, Agilent's Life Sciences
Group President, commented, "As one of the fastest developing infrastructure
and business regions in the world, Vietnam is a critical component in
Agilent's key emerging markets strategy. We look forward now to directly
participating with customers to deliver the products and solutions in
electronics, chemical analysis and life sciences that will help accelerate
their work and ultimately contribute to the growth of Vietnam." The Full
Research Report on Agilent Technologies Inc. - including full detailed
breakdown, analyst ratings and price targets - is available to download free
of charge at: [http://www.wsreports.com/r/full_research_report/075f_A]

--

Thermo Fisher Scientific Inc. Research Report

On May 23, 2013, Thermo Fischer Scientific Inc.'s (Thermo Fisher) Board of
Directors declared a quarterly cash dividend of $0.15 per share. The dividend
will be paid on July 15, 2013 to shareholders of record as of June 17, 2013.
The Full Research Report on Thermo Fisher Scientific Inc. - including full
detailed breakdown, analyst ratings and price targets - is available to
download free of charge at:
[http://www.wsreports.com/r/full_research_report/45ea_TMO]

--

BG Medicine, Inc. Research Report

On May 28, 2013, BG Medicine, Inc. (BG Medicine) announced the presentation of
new clinical research data on the BGM Galectin-3 test in heart disease at the
2013 European Society of Cardiology Heart Failure Congress (ESC-HF) in Lisbon,
Portugal. Among the highlights was a late-breaking oral presentation of
results from the Aldo-DHF Biomarker Substudy, which demonstrated the
usefulness of galectin-3 testing for assessing functional capacity and
clinical prognosis in patients diagnosed with a form of heart failure known as
Heart Failure with Preserved Ejection Fraction (HFpEF). HFpEF is the fastest
growing type of clinical heart failure in the United States and Europe,
disproportionately affecting women and accounting for one-third to one-half of
all hospital admissions for heart failure. Paul Sohmer, President and CEO of
BG Medicine, stated, "The data presented at ESC-HF further demonstrate that
galectin-3 may be an important determinant of heart failure risk across the
clinical spectrum of disease. Unplanned hospitalizations of patients with
heart failure are a major cost burden on healthcare systems, particularly
among patients with a diagnosis of HFpEF, one of the fastest growing but most
difficult types of heart failure to identify and treat. The data presented at
ESC-HF suggest that galectin-3 testing may help to identify HFpEF patients who
are at risk of near-term adverse events." The Full Research Report on BG
Medicine, Inc. - including full detailed breakdown, analyst ratings and price
targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/e185_BGMD]

--

Quest Diagnostics Inc. Research Report

On May 21, 2013, world's leading provider of diagnostic services, Quest
Diagnostics Inc. (Quest Diagnostics), announced that its Board of Directors
declared a quarterly cash dividend of $0.30 per share. The dividend is payable
on July 17, 2013 to the shareholders of record as of July 2, 2013. The Full
Research Report on Quest Diagnostics Inc. - including full detailed breakdown,
analyst ratings and price targets - is available to download free of charge
at: [http://www.wsreports.com/r/full_research_report/0cb6_DGX]

--

Ironwood Pharmaceuticals, Inc. Research Report

On May 21, 2013, Ironwood Pharmaceuticals, Inc. (Ironwood Pharmaceuticals)
announced the pricing of an underwritten public offering of 10.5 million
shares of its Class A common stock at a price of $13 per share to the public.
The gross proceeds to Ironwood Pharmaceuticals from this offering are expected
to be approximately $136.5 million, before deducting underwriting discounts
and commissions, and other estimated offering expenses payable by the Company.
The offering is expected to close on May 24, 2013, subject to the satisfaction
of customary closing conditions. The Company plans to use the net proceeds
from this offering to support the launch of LINZESS (linaclotide) in the US
and to fund additional linaclotide development opportunities to strengthen the
clinical profile of LINZESS. The Full Research Report on Ironwood
Pharmaceuticals, Inc. - including full detailed breakdown, analyst ratings and
price targets - is available to download free of charge at:
[http://www.wsreports.com/r/full_research_report/d5cb_IRWD]

----

EDITOR NOTES:

1.This is not company news. We are an independent source and our views do
    not reflect the companies mentioned.
2.Information in this release is fact checked and produced on a best efforts
    basis and reviewed by a CFA. However, we are only human and are prone to
    make mistakes. If you notice any errors or omissions, please notify us
    below.
3.This information is submitted as a net-positive to companies mentioned, to
    increase awareness for mentioned companies to our subscriber base and the
    investing public.
4.If you wish to have your company covered in more detail by our team, or
    wish to learn more about our services, please contact us at
    pubco@EquityNewsNetwork.com.
5.For any urgent concerns or inquires, please contact us at
    compliance@EquityNewsNetwork.com.
6.Are you a public company? Would you like to see similar coverage on your
    company? Send us a full investors' package to
    research@EquityNewsNetwork.com for consideration.

COMPLIANCE PROCEDURE

Content is researched, written and reviewed on a best-effort basis. This
document, article or report is prepared and authored by Equity News Network.
An outsourced research services provider has, through Chartered Financial
Analysts, only reviewed the information provided by Equity News Network in
this article or report according to the Procedures outlined by Equity News
Network. Equity News Network is not entitled to veto or interfere in the
application of such procedures by the outsourced provider to the articles,
documents or reports, as the case may be.

NOT FINANCIAL ADVICE

Equity News Network makes no warranty, expressed or implied, as to the
accuracy or completeness or fitness for a purpose (investment or otherwise),
of the information provided in this document. This information is not to be
construed as personal financial advice. Readers are encouraged to consult
their personal financial advisor before making any decisions to buy, sell or
hold any securities mentioned herein.

NO WARRANTY OR LIABILITY ASSUMED

Equity News Network is not responsible for any error which may be occasioned
at the time of printing of this document or any error, mistake or shortcoming.
No liability is accepted by Equity News Network whatsoever for any direct,
indirect or consequential loss arising from the use of this document. Equity
News Network expressly disclaims any fiduciary responsibility or liability for
any consequences, financial or otherwise arising from any reliance placed on
the information in this document. Equity News Network does not (1) guarantee
the accuracy, timeliness, completeness or correct sequencing of the
information, or (2) warrant any results from use of the information. The
included information is subject to change without notice.

SOURCE Wall Street Reports

Contact: WSReports.com, +1-310-496-8071